Doximity, Inc. (NYSE:DOCS) is one of the most oversold healthcare stocks to invest in. On April 16, BofA cut the price target on Doximity, Inc. (NYSE:DOCS) to $47 from $56, reaffirming a Buy rating on the shares and telling investors that the firm’s sixteenth quarterly survey on pharma advertising had “mixed, but somewhat positive takeaways”. It further reported that Doximity, Inc.’s specifics were “also mixed-to-positive,” with the strongest outlook for overall spend growth in the history of the survey. However, the trends reflected a notably weaker outlook on the company’s fast-growing point of care module. The firm thus lowered its revenue estimate for fiscal year 2027 and target EBITDA multiple, as visibility into an accelerated shift in spend to HCP channels is more limited.
Doximity, Inc. also received a rating update from KeyBanc on April 13. The firm lowered the price target on the stock to $30 from $38 and maintained an Overweight rating on the shares.
Doximity, Inc. is involved in the development and operation of an online platform for medical professionals. The company employs its cloud-based software to allow users to coordinate patient care, collaborate with their colleagues, conduct virtual patient visits, manage their careers, and more.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
